Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy

2014 ◽  
Vol 37 (12) ◽  
pp. 1588-1598 ◽  
Author(s):  
Jun-Ren Zhu ◽  
Shu-Yang Zhang ◽  
Ping-Jin Gao
Keyword(s):  
Olmesartan Medoxomil ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Hypertensive Patients ◽  
Dose Combination

scholarly journals Efficacy and Safety of a Lercanidipine/Enalapril Fixed-Dose Combination in Hypertensive Patients in Portugal

Drugs in R&D ◽  
2014 ◽  
Vol 14 (2) ◽  
pp. 147-154 ◽  
Author(s):  
João Maldonado ◽  
Telmo Pereira ◽  
Alfredo Tavares
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Hypertensive Patients ◽  
Dose Combination

scholarly journals Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial

2018 ◽  
Vol 20 (10) ◽  
pp. 1473-1484 ◽  
Author(s):  
David J. Collier ◽  
Attila Juhasz ◽  
Enrico Agabiti-Rosei ◽  
Eric Lloyd ◽  
Michie Hisada ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Hypertensive Patients ◽  
Dose Combination ◽  
Azilsartan Medoxomil

scholarly journals Efficacy and Safety of Triple Drug Fixed-Dose Combination of Telmisartan, Amlodipine and Hydrochlorthiazide in the Management of Hypertension

2015 ◽  
Vol 16 (1) ◽  
pp. 18-22
Author(s):  
Faruqui A Arif ◽  
A Amlaselvam ◽  
Renuka Sriram
Keyword(s):  
Blood Pressure ◽  
Systolic Blood Pressure ◽  
Fixed Dose Combination ◽  
Antihypertensive Drug Therapy ◽  
Fixed Dose ◽  
Age Group ◽  
Optimal Management ◽  
Efficacy And Safety ◽  
Hypertensive Patients ◽  
Dose Combination

Effective BP control is far away from reality in many patients in spite of advancements in many classes of antihypertensive drug therapy. Use of triple drug combination in the management of hypertension have already been established, however this study was conducted to evaluate the efficacy and safety of triple drug fixed dose combination of Telmisartan 40 mg, Amlodipine 5 mg and Hydrochlorothiazide 12.5mg. 69 hypertensive patients with seating cuff systolic blood pressure e” 160 mmHg and diastolic blood pressure e”100 mmHg were enrolled in the study. Patients were prescribed to take triple drug fixed dose combination for 120 days. Patients were evaluated on 30th, 60th and 120th days of treatment. There was statistically significant (p<0.0001) decrease in systolic blood pressure from baseline to 30th, 60th and 120th day of treatment mean±SD (166±18.6 mmHg vs.147±16.1, 137±14.7 and 130±13.9 mmHg) respectively. Similar to SBP, decrease in DBP was highly significant (p<0.0001) from the baseline to the 30th, 60th and 120th day of treatment (104±11.5 mmHg vs. 93.7±12.3, 89±10.2 and 84.5±8.98 mmHg respectively). Moreover at the end of the study period of 120 days 85.7% and 87.8% patients of age group >60 years and <60 years respectively achieved the JNC VIII recommended goal. This triple drug fixed dose combination of Telmisartan, Amlodipine and hydrochlorothiazide was found to be effective and safe option for the optimal management of hypertension.DOI: http://dx.doi.org/10.3329/jom.v16i1.22383 J MEDICINE 2015; 16 : 18-22

scholarly journals Practical efficacy and safety of Konsilar D24 in patients with hypertension: data from the KONSONANS program

2021 ◽  
Vol 26 (9) ◽  
pp. 4651
Author(s):  
A. O. Konradi ◽  
A. S. Galyavich ◽  
V. V. Kashtalap ◽  
Yu. M. Lopatin ◽  
N. P. Lyamina ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Antihypertensive Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Baseline Body Mass Index ◽  
Efficacy And Safety ◽  
Open Label ◽  
Hypertensive Patients ◽  
Dose Combination

Aim. In practice, to evaluate the efficacy, safety and long-term adherence to therapy with a fixed-dose combination of ramipril/indapamide (Konsilar-D24) in patients with grade 1-2 hypertension (HTN) who have not achieved blood pressure (BP) control with prior therapy or have not taken antihypertensive therapy.Material and methods. This multicenter open-label observational program included 524 patients with grade 1-2 HTN who did not take antihypertensive therapy or did not reach the target BP level with mono or dual antihypertensive therapy, as well as patients shifted to Konsilar-D24 therapy no later than two weeks before the start of the program. All patients signed a written informed consent to participate in the program. The safety analysis set includes all patients who have taken at least one dose of a fixed-dose combination of ramipril/indapamide and have visited physician at least once during the program. The effectiveness analysis set included all patients in the safety population who completed the study in accordance with protocol (n=511). Clinical systolic blood pressure (SBP), diastolic BP (DBP) and heart rate were assessed at baseline, as well as at 0,5, 1, 3 and 6 months of treatment. A post hoc subgroup analysis of changes in BP and heart rate was performed depending on age, sex and baseline body mass index.Results. The fixed-dose combination of ramipril with indapamide significantly reduced SBP and DBP after 2-week treatment (-20,9±10,1 mm Hg; pConclusion. Despite the limitations inherent in observational studies, the KONSONANS program has demonstrated high efficacy and safety of fixed-dose combination of ramipril/indapamide taken once a day in hypertensive patients. Ramipril/indapamide fixed-dose combination therapy significantly improved BP control and achieved even lower individual target BP levels in the majority of hypertensive patients.

Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use

Pneumologie ◽  
2016 ◽  
Vol 70 (S 01) ◽  
Author(s):  
ED Bateman ◽  
K Chapman ◽  
S Rennard ◽  
L Rekeda ◽  
M Moya ◽  
...  
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Dose Combination
Sign in / Sign up

Export Citation Format

Share Document